News
We send the latest information from SMC Laboratories.
Announcement of webinar: THRβ agonist and preclinical pharmacology study using by STAM™ mice
Today, we are excited to invite you to join our webinar that will be taking place on June 20 from 9:30 AM (JST…
Drug efficacy evaluation study for fibrotic diseases involving multiple organs
If the therapeutic drug you are developing targets a factor that is related to a multi-organ pathology, such a…
Poster presentation selected for the EASL Congress 2024, data on STAM mice in the field of Immune-oncology
We are pleased to announce that the latest pathology and pathogenesis data in the field of immuno-oncology on …
SMC will be exhibiting at The 110th General Meeting of the Japanese Society of Gastroenterology
We are pleased to announce that SMC Laboratories will be exhibiting at The 110th General Meeting of the Japane…
【Breaking News!】 First MASH treatment approved by FDA
On March 14th, The United States Food and Drug Administration (FDA) announced their approval of Rezdiffra (res…
What is the best non-clinical liver cancer model with 100% cancer incidence rate and suitable for liver cancer assessment?
If you are considering a drug evaluation study for liver cancer using a mouse model, our STAM™-HCC/IO⁺ m…
The [optimal disease model] that maximizes your research outputs.
The bleomycin-induced pulmonary fibrosis mouse model is commonly used to replicate the pathogenesis of IPF in …
【Case Study】Why do disease model mice change the outcomes?
If you are considering using a lung fibrosis model in a drug efficacy study, you can maximize the efficacy of …
Introduction of [Pathway MAP of MASH compounds] to accelerate your research
When conducting non-clinical research, it is important to choose an appropriate mouse model that reproduces hu…
Preclinical COPD study with positive controls, Roflumilast
Today, we share an update regarding new preclinical service. It is now possible to use a positive control (Rof…